标题
Harnessing synthetic lethal interactions in anticancer drug discovery
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume 10, Issue 5, Pages 351-364
出版商
Springer Nature
发表日期
2011-04-30
DOI
10.1038/nrd3374
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Role of Tyrosine Kinase Inhibitors in Lung Cancer
- (2012) J. Ansari et al. Anti-Cancer Agents in Medicinal Chemistry
- Parallel High-Throughput RNA Interference Screens Identify PINK1 as a Potential Therapeutic Target for the Treatment of DNA Mismatch Repair-Deficient Cancers
- (2011) S. A. Martin et al. CANCER RESEARCH
- Targeting cancer cells by synthetic lethality
- (2011) Denise A. Chan et al. CELL CYCLE
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
- (2011) Ignacio Varela et al. NATURE
- Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
- (2011) Thomas Force et al. NATURE REVIEWS DRUG DISCOVERY
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1
- (2010) Sarah A. Martin et al. CANCER CELL
- Poly(ADP-Ribose) Polymerase Inhibitor Induces Accelerated Senescence in Irradiated Breast Cancer Cells and Tumors
- (2010) E. V. Efimova et al. CANCER RESEARCH
- Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
- (2010) P. Gottipati et al. CANCER RESEARCH
- PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) B. McEllin et al. CANCER RESEARCH
- Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
- (2010) N. Chan et al. CANCER RESEARCH
- Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
- (2010) O. Gilad et al. CANCER RESEARCH
- Slaying RAS with a synthetic lethal weapon
- (2010) Archana Bommi-Reddy et al. CELL RESEARCH
- Targeting cancer cells through autophagy for anticancer therapy
- (2010) Sandra Turcotte et al. CURRENT OPINION IN CELL BIOLOGY
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- PARP inhibition in BRCA-mutated breast and ovarian cancers
- (2010) Stephen L Chan et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Sensitization to Radiation and Alkylating Agents by Inhibitors of Poly(ADP-ribose) Polymerase Is Enhanced in Cells Deficient in DNA Double-Strand Break Repair
- (2010) D. A. Loser et al. MOLECULAR CANCER THERAPEUTICS
- PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations
- (2010) Lisa Hutchinson Nature Reviews Clinical Oncology
- Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase
- (2010) D. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rad52 inactivation is synthetically lethal with BRCA2 deficiency
- (2010) Z. Feng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Finding and Drugging the Vulnerabilities of RAS-Dependent Cancers
- (2009) Charles L. Sawyers CELL
- Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
- (2009) Claudia Scholl et al. CELL
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma
- (2009) A. C. Young et al. CLINICAL CANCER RESEARCH
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
- Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies
- (2009) H. Willers et al. MOLECULAR CANCER RESEARCH
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
- (2009) Etienne Meylan et al. NATURE
- Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
- (2009) Pasi A. Jänne et al. NATURE REVIEWS DRUG DISCOVERY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oxygen Consumption Can Regulate the Growth of Tumors, a New Perspective on the Warburg Effect
- (2009) Yijun Chen et al. PLoS One
- Synthetic lethality: a framework for the development of wiser cancer therapeutics
- (2009) William G Kaelin Genome Medicine
- Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
- (2008) E D Michelakis et al. BRITISH JOURNAL OF CANCER
- A Molecule Targeting VHL-Deficient Renal Cell Carcinoma that Induces Autophagy
- (2008) Sandra Turcotte et al. CANCER CELL
- Recent advances in p53 research: an interdisciplinary perspective
- (2008) M Olivier et al. CANCER GENE THERAPY
- Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance
- (2008) N. Chan et al. CANCER RESEARCH
- Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
- (2008) B. Evers et al. CLINICAL CANCER RESEARCH
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Translation of Targeted Oncolytic Virotherapeutics from the Lab into the Clinic, and Back Again: A High-Value Iterative Loop
- (2008) Ta-Chiang Liu et al. MOLECULAR THERAPY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen
- (2008) A. Bommi-Reddy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CDK inhibitors in cancer therapy: what is next?
- (2007) Marcos Malumbres et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started